PepGen (PEPG) Projected to Post Quarterly Earnings on Wednesday

PepGen (NASDAQ:PEPGGet Free Report) will likely be announcing its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

PepGen (NASDAQ:PEPGGet Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.13. On average, analysts expect PepGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PepGen Stock Down 10.8 %

PEPG stock opened at $2.81 on Tuesday. The firm has a 50 day moving average of $2.35 and a 200 day moving average of $5.61. The stock has a market capitalization of $91.86 million, a PE ratio of -0.94 and a beta of 1.53. PepGen has a 52 week low of $1.16 and a 52 week high of $19.30.

Wall Street Analyst Weigh In

A number of research firms recently commented on PEPG. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of PepGen in a research note on Monday, February 24th. Wedbush lowered their target price on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, Bank of America cut shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a research note on Monday, December 16th.

Read Our Latest Report on PepGen

PepGen Company Profile

(Get Free Report)

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

Featured Stories

Earnings History for PepGen (NASDAQ:PEPG)

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.